FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294647389> ?p ?o ?g. }

• W4294647389 abstract "Abstract Background Axial involvement constitutes a specific domain of psoriatic arthritis (PsA). Interleukin (IL)-23 inhibitors have demonstrated improvement in axial PsA (axPsA) symptoms, but have not shown efficacy in treating ankylosing spondylitis (AS), suggesting differences in axPsA processes and treatments. In a post hoc, pooled analysis of patients with investigator- and imaging-confirmed sacroiliitis in two phase 3, randomized, placebo-controlled studies (DISCOVER-1 and DISCOVER-2), patients treated with guselkumab, an IL-23p19 inhibitor, had greater axial symptom improvements compared with placebo. Confirmatory imaging at baseline was restricted to the sacroiliac (SI) joints, occurred prior to/at screening, and was locally read. Methods The STAR study will prospectively assess efficacy outcomes in PsA patients with magnetic resonance imaging (MRI)-confirmed axial inflammation. Eligible, biologic-naïve patients with PsA ( N = 405) for ≥ 6 months and active disease (≥ 3 swollen and ≥ 3 tender joints, C-reactive protein [CRP] ≥ 0.3 mg/dL) despite prior non-biologic disease-modifying antirheumatic drugs, apremilast, and/or nonsteroidal anti-inflammatory drugs will be randomized (1:1:1) to guselkumab every 4 weeks (Q4W); guselkumab at week (W) 0, W4, then every 8 weeks (Q8W); or placebo with crossover to guselkumab at W24, W28, then Q8W. Patients will have Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ≥ 4, spinal pain component score (0–10 visual analog scale) ≥ 4, and screening MRI-confirmed axial involvement (positive spine and/or SI joints according to centrally read Spondyloarthritis Research Consortium of Canada [SPARCC] score ≥ 3 in ≥ 1 region). The primary endpoint is mean change from baseline in BASDAI at W24; multiplicity controlled secondary endpoints at W24 include AS Disease Activity Score employing CRP (ASDAS), Disease Activity Index for PsA (DAPSA), Health Assessment Questionnaire – Disability Index (HAQ-DI), Investigator’s Global Assessment of skin disease (IGA), and mean changes from baseline in MRI SI joint SPARCC scores. Centrally read MRIs of spine and SI joints (scored using SPARCC) will be obtained at W0, W24, and W52, with readers blinded to treatment group and timepoint. Treatment group comparisons will be performed using a Cochran-Mantel-Haenszel or chi-square test for binary endpoints and analysis of covariance, mixed model for repeated measures, or constrained longitudinal data analysis for continuous endpoints. Discussion This study will evaluate the ability of guselkumab to reduce both axial symptoms and inflammation in patients with active PsA. Trial registration This trial was registered at ClinicalTrials.gov, NCT04929210 , on 18 June 2021. Protocol version: Version 1.0 dated 14 April 2021." @default.
• W4294647389 created "2022-09-05" @default.
• W4294647389 creator A5001483785 @default.
• W4294647389 creator A5002054186 @default.
• W4294647389 creator A5002895469 @default.
• W4294647389 creator A5015084747 @default.
• W4294647389 creator A5027011800 @default.
• W4294647389 creator A5029965399 @default.
• W4294647389 creator A5033638242 @default.
• W4294647389 creator A5034020691 @default.
• W4294647389 creator A5053353962 @default.
• W4294647389 creator A5058110978 @default.
• W4294647389 creator A5064220409 @default.
• W4294647389 creator A5072083932 @default.
• W4294647389 creator A5072664936 @default.
• W4294647389 creator A5074069242 @default.
• W4294647389 creator A5081778211 @default.
• W4294647389 creator A5086513788 @default.
• W4294647389 creator A5091351742 @default.
• W4294647389 date "2022-09-05" @default.
• W4294647389 modified "2023-10-14" @default.
• W4294647389 title "Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial" @default.
• W4294647389 cites W1895420435 @default.
• W4294647389 cites W1979387382 @default.
• W4294647389 cites W1985004174 @default.
• W4294647389 cites W1988086236 @default.
• W4294647389 cites W1993264600 @default.
• W4294647389 cites W1997929321 @default.
• W4294647389 cites W2017932566 @default.
• W4294647389 cites W2078332400 @default.
• W4294647389 cites W2079392881 @default.
• W4294647389 cites W2099151126 @default.
• W4294647389 cites W2103778140 @default.
• W4294647389 cites W2103874459 @default.
• W4294647389 cites W2114142124 @default.
• W4294647389 cites W2131554848 @default.
• W4294647389 cites W2135336890 @default.
• W4294647389 cites W2151319888 @default.
• W4294647389 cites W2158174717 @default.
• W4294647389 cites W2162319272 @default.
• W4294647389 cites W2163387772 @default.
• W4294647389 cites W2167551680 @default.
• W4294647389 cites W2171811563 @default.
• W4294647389 cites W2258730682 @default.
• W4294647389 cites W2336136362 @default.
• W4294647389 cites W2411041938 @default.
• W4294647389 cites W2518865922 @default.
• W4294647389 cites W2788828749 @default.
• W4294647389 cites W2790567029 @default.
• W4294647389 cites W2810397534 @default.
• W4294647389 cites W2828329901 @default.
• W4294647389 cites W2891366322 @default.
• W4294647389 cites W2895929438 @default.
• W4294647389 cites W2902815229 @default.
• W4294647389 cites W2906852571 @default.
• W4294647389 cites W2979552390 @default.
• W4294647389 cites W2980140632 @default.
• W4294647389 cites W3004889210 @default.
• W4294647389 cites W3005364164 @default.
• W4294647389 cites W3011285271 @default.
• W4294647389 cites W3012050575 @default.
• W4294647389 cites W3109370940 @default.
• W4294647389 cites W3128854736 @default.
• W4294647389 cites W3134108418 @default.
• W4294647389 cites W3157612851 @default.
• W4294647389 cites W3173649223 @default.
• W4294647389 cites W3174072327 @default.
• W4294647389 cites W4205914864 @default.
• W4294647389 cites W4255613904 @default.
• W4294647389 doi "https://doi.org/10.1186/s13063-022-06589-y" @default.
• W4294647389 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36064592" @default.
• W4294647389 hasPublicationYear "2022" @default.
• W4294647389 type Work @default.
• W4294647389 citedByCount "12" @default.
• W4294647389 countsByYear W42946473892022 @default.
• W4294647389 countsByYear W42946473892023 @default.
• W4294647389 crossrefType "journal-article" @default.
• W4294647389 hasAuthorship W4294647389A5001483785 @default.
• W4294647389 hasAuthorship W4294647389A5002054186 @default.
• W4294647389 hasAuthorship W4294647389A5002895469 @default.
• W4294647389 hasAuthorship W4294647389A5015084747 @default.
• W4294647389 hasAuthorship W4294647389A5027011800 @default.
• W4294647389 hasAuthorship W4294647389A5029965399 @default.
• W4294647389 hasAuthorship W4294647389A5033638242 @default.
• W4294647389 hasAuthorship W4294647389A5034020691 @default.
• W4294647389 hasAuthorship W4294647389A5053353962 @default.
• W4294647389 hasAuthorship W4294647389A5058110978 @default.
• W4294647389 hasAuthorship W4294647389A5064220409 @default.
• W4294647389 hasAuthorship W4294647389A5072083932 @default.
• W4294647389 hasAuthorship W4294647389A5072664936 @default.
• W4294647389 hasAuthorship W4294647389A5074069242 @default.
• W4294647389 hasAuthorship W4294647389A5081778211 @default.
• W4294647389 hasAuthorship W4294647389A5086513788 @default.
• W4294647389 hasAuthorship W4294647389A5091351742 @default.
• W4294647389 hasBestOaLocation W42946473891 @default.
• W4294647389 hasConcept C126322002 @default.
• W4294647389 hasConcept C142724271 @default.
• W4294647389 hasConcept C168563851 @default.
• W4294647389 hasConcept C203092338 @default.
• W4294647389 hasConcept C204787440 @default.

• next